In this review:
- First-line anti-PD-(L)1 with/ without chemotherapy in NSCLC
- Immune checkpoint inhibitors in NSCLC according to KRAS status
- Ramucirumab plus pembrolizumab for advanced NSCLC
- KRYSTAL-1: Adagrasib in NSCLC with a KRASG12C mutation
- Amivantamab and lazertinib in EGFR-mutant NSCLC after progression
- Amivantamab in NSCLC with MET
- Atezolizumab carboplatin and etoposide with/without tiragolumab in ES-SCLC
- Serplulimab plus chemotherapy first-line for ES-SCLC
- Nivolumab plus chemotherapy for resectable stage IIIA NSCLC
- Quality metrics and survival following lung cancer resection
Please login below to download this issue (PDF)